Outcome of Adolescents with Acute Lymphoblastic Leukemia Treated by Pediatrics versus Adults Protocols

Table 1

Adults adopted BFM regimen.

Prephase if (TLC > 2.500 cells/mm^3 and/or oraganomegaly)
Vincristine	2 mg	IV	D1
Dexamethasone	10 mg/m^2	IV	(D1–7)
Phase I induction
Vincristine	2 mg	IV	(D1, 8, 15, 22)
Doxorubicin	45 mg/m^2	IV	(D1, 8, 15, 22)
L-asparaginase	5000 u/m^2	IM	(D15–28)
Dexamethasone	10 mg/m^2	IV	11 days (if patients received prophase 7 days so to complete 4 more days only)
Methotrexate	15 mg	IT	D1
Phase II induction
Cyclophosphamide	650 mg/m^2	IV	(D1, 14, 28)
Cytarabine	75 mg/m^2	IV	(D3, 4, 5, 6 and 9, 10, 11, 12 and 16, 17, 18, 19 and 23, 24, 25, 26)
Methotrexate	15 mg	IT	Given as 4 weekly (D1, 8, 15, 22)
Cranial prophylaxis			Irradiation (24 Gy)
Phase I consolidation
Vincristine	2 mg	IV	(D1, 8, 15, 22)
Doxorubicin	45 mg/m^2	IV	(D1, 8, 15, 22)
Dexamethasone	10 mg/m^2	IV	For 11 days
Phase II consolidation
Cyclophosphamide	650 mg/m^2	IV	(D1, 14, 28)
Cytarabine	75 mg/m^2	IV	(D3, 4, 5, 6 and 9, 10, 11, 12 and 16, 17, 18, 19 and 23, 24, 25, 26)
Methotrexate	15 mg	IT	4 weekly (D1, 8, 15, 22)
Maintenance will be given for two years
6-Mercaptopurine	75 mg/m^2	PO	Daily PO
Methotrexate	20 mg/m^2	IV	Once weekly
Triple IT cytarabine 40 mg, MTX 15 mg, Dexamethasone 4 mg			Every 2 months till the end of maintenance

D: Day, Gy: Gray, IT: intrathecal, MTX: Methotrexate, PO: per oral, TLC: total leucocytes count.